{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017572","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.301993+00:00","generated_at":"2026-06-21T21:01:04.004837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Virios reports Q3 net loss $2.6M, cash $9.8M, advances IMC-1 to Phase 3 based on post-hoc FORTRESS analysis","bullets":["Net loss of $2.6M ($0.28 per share) for Q3 2022 vs $4.1M ($0.49) in Q3 2021.","Cash totaled $9.8M as of Sep 30, 2022; company expects to fund operations through end of 2023.","Post-hoc FORTRESS analysis shows significant pain reduction in fibromyalgia patients naive to prior trials/treatment.","Company plans to meet with FDA to discuss advancing IMC-1 into Phase 3 development.","Raised $5M in September 2022 equity capital to support IMC-1 development and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017572","json":"https://secwatch.observer/filing/0001558370-22-017572.json","markdown":"https://secwatch.observer/filing/0001558370-22-017572.md","text":"https://secwatch.observer/filing/0001558370-22-017572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/0001558370-22-017572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/tmb-20221114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:01:04.004837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b61c84734b47b48afe1d9a390191dc2c2a7189d","claim":"Dogwood Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $2.6 million, EPS $0.28 basic and diluted net loss per share.","evidence_excerpt":"Net loss for the third quarter ended September 30, 2022 was $2.6 million, or $0.28 basic and diluted net loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/0001558370-22-017572-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$2.6 million"},{"label":"EPS","value":"$0.28 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}